Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Saskatchewan

$17,500.00

Funding for Clinical Study on Tiotropium Efficacy on Allergen Induced Early Asthmatic Responses

FY 2020-21

Summary
Inhaled tiotropium (Spiriva Respimat®) is a medication used to treat respiratory conditions including chronic obstructive pulmonary disease (COPD) and asthma. Technically, tiotropium is referred to as a long acting muscarinic antagonist or ""LAMA"". The term long acting suggests the drug is used once a day. Muscarinic refers to a type of receptor on airway smooth muscle involved in causing bronchoconstriction or a tightening of the airway which makes breathing more difficult. Antagonist means it blocks or inhibits the effect. Therefore, tiotropium blocks muscarinic receptors on airway smooth muscle and prevents bronchoconstriction. Recent non-human research suggests tiotropium may also have anti-inflammatory effects. The potential anti-inflammatory effect of tiotropium is relevant to individuals with asthma, allergic asthma in particular, since allergen exposure not only causes acute bronchoconstriction (i.e. asthma symptoms such as shortness of breath, chest tightness and wheezing) but also leads to airway inflammation. The purpose of this study is to investigate the protective effects of tiotropium on the response to allergen exposure in individuals with mild allergic asthma in terms of both acute bronchoconstriction and airway inflammation.
Program
Master's Award: Canada Graduate Scholarships
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449720
Name
Cropper Kayla J
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Funding for Clinical Study on Tiotropium Efficacy on Allergen Induced Early Asthmatic Responses
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allergen Inhalation Challenge; Allergic Asthma; Asthma; Early Asthmatic Response; Long-Acting Muscarinic Antagonist
Abstract
Inhaled tiotropium (Spiriva Respimat®) is a medication used to treat respiratory conditions including chronic obstructive pulmonary disease (COPD) and asthma. Technically, tiotropium is referred to as a long acting muscarinic antagonist or ""LAMA"". The term long acting suggests the drug is used once a day. Muscarinic refers to a type of receptor on airway smooth muscle involved in causing bronchoconstriction or a tightening of the airway which makes breathing more difficult. Antagonist means it blocks or inhibits the effect. Therefore, tiotropium blocks muscarinic receptors on airway smooth muscle and prevents bronchoconstriction. Recent non-human research suggests tiotropium may also have anti-inflammatory effects. The potential anti-inflammatory effect of tiotropium is relevant to individuals with asthma, allergic asthma in particular, since allergen exposure not only causes acute bronchoconstriction (i.e. asthma symptoms such as shortness of breath, chest tightness and wheezing) but also leads to airway inflammation. The purpose of this study is to investigate the protective effects of tiotropium on the response to allergen exposure in individuals with mild allergic asthma in terms of both acute bronchoconstriction and airway inflammation.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cropper, Kayla J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Saskatchewan - $17,500 Grant (2020-21) | Canada Spends